#bio-path

Bio-Path Holdings (NASDAQ: BPTH): 2019 Earnings Snapshot

— Bio-Path Holdings Inc. (NASDAQ: BPTH) reported a loss of $3.24 share for the full year 2019, wider than a loss of $14.38 per share in the previous year.

— Research and development expenses remained flat from the last year at $4.6 million.

— General and administrative expenses were $4.1 million during the year ended December 31, 2019, up 21% from last year, primarily due to increased legal…

Bio-Path’s loss expands in Q2

Biotech company Bio-Path Holdings (NASDAQ: BPTH) reported a loss of $2.5 million or $0.87 per share for the second quarter ended June 30, 2019, compared to a loss of $1.7 million or $2.96 per share for the second quarter ended June 30, 2018. Bio-Path has not generated significant revenues to date. The company’s revenue generation in the future depends on the successful development and eventual…

Bio-Path likely to report wider Q2 loss on Aug. 15

Bio-Path Holdings (NASDAQ: BPTH) is expected to continue incurring significant operating losses in the second quarter. Also, the losses are likely to increase substantially as the biotech company expand its drug development programs and commercialization efforts. The company is set to release its second-quarter earnings results on Thursday before the bell.

The company had an accumulated deficit…

Bio-Path’s stock tanks as company delivers loss for Q1

Bio-Path Holdings Inc.’s (NASDAQ: BPTH) shares were down 2.6% in morning hours on Thursday after the company reported its first quarter 2019 earnings results.

The bio-tech company reported a net loss of $1.5 million, or $0.89 per share, for the quarter compared to a loss of $1.9 million, or $3.38 per share, in the prior-year period.

R&D expenses decreased to $0.4 million from $0.9…